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Abstract
This is the first utilization of advanced analytical electron microscopy methods, including high-
resolution transmission electron microscopy (HRTEM), high angle annular dark field scanning 
TEM (HAADF-STEM), electron energy loss spectroscopy (EELS), and energy-dispersive X-ray 
spectroscopy (EDS) mapping to characterize the organ-specific bioprocessing of a relatively inert 
nanomaterial (nanoceria). Liver and spleen samples from rats given a single iv infusion of 
nanoceria were obtained after prolonged (90 days) in vivo exposure. These advanced analytical 
electron microscopy methods were applied to elucidate the organ specific cellular and subcellular 
fate of nanoceria after its uptake. Nanoceria is bioprocessed differently in the spleen than in the 
liver.
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Introduction
The long-term fate of nanomaterials is not well understood. Concerns about adverse human 
health impacts due to a single or repeated exposure may deter some nanotechnology 
developments from reaching commercial implementation. A greater understanding of the 
roles of nanoparticle biodistribution and fate, interactions with tissues, and in vivo effects is 
needed to alleviate some of the reservations related to their widespread use. For progress to 
be made in developing better safety assessment methodologies and understanding the 
toxicity of nanomaterials, it is necessary to recognize the fundamental processes occurring at 
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the bio-nano interface and the mechanisms/chemistries involved (Nel et al. 2009; Graham et 
al. 2017a; Giri et al. 2013; Pulido-Reyes et al. 2017). One approach is the utilization of 
advanced high-resolution transmission electron microscopy (HRTEM) coupled with in situ 
spectroscopic methods (energy-dispersive X-ray spectroscopy, EDS-mapping) and electron 
energy loss spectroscopy (EELS). The beginnings of this field have been described (Graham 
et. al. 2017a). Future strides in this area will be aided by improvements in EDS and EELS 
detection abilities (FEI Talos and NION UltraSTEM instruments and EELS resolution of 10 
mV with spectral quality on the order of an x-ray synchrotron), and the online availability of 
new experimental and computational spectral databases. A comprehensive experimental and 
theoretical x-ray absorption and EELS database is currently being developed as part of the 
Materials Project at Lawrence Berkeley National Laboratory (Dozier et. al. 2017). It 
provides online programs and tools to access structural and electronic information among a 
long list of properties for various nanoparticles and metastable phases that can be used to 
compare with experimental or analytical datasets. This is particularly important for the 
recently described in vivo transformation and subsequent formation of 2nd generation 
nanoparticles at the cellular and subcellular level (Graham et al. 2014; Graham et al. 2017a). 
Little is known about underlying mechanisms that control bioprocessing which modifies the 
physicochemical properties of the primary particles. We previously defined in vivo 
processing as the dynamic chemical and physical breakdown and subsequent transformation 
of nanoparticles at the cellular and subcellular levels, which occurs when particle stability is 
compromised (Graham et al. 2014). As a result, new reaction products are formed, and the 
released ions may be transported and form new nuclei and 2nd generation nanoparticles 
Graham et al. 2017a).
Nanomaterials can be bioprocessed/biodegraded in vivo, most likely through dissolution, 
resulting in structural loss and change of their physicochemical properties and activity, 
including toxicity (Soenen et al. 2015). Transport of biosoluble constituents can result in the 
formation of new phases close by or remotely. Nanoscale barium sulphate (Konduru et al. 
2014) and silver (Lee et al. 2013) undergo relatively rapid dissolution in vivo while carbon-
based nanomaterials are quite biopersistent, although carbon nanotubes have been shown to 
undergo peroxidase-mediated degradation (Vlasova et al. 2016; Nunes et al. 2012; Shvedova 
et al. 2012). There is particular concern about biopersistent nanomaterials, their ultimate 
fate, and potential toxicity induced by their prolonged persistence (Arts et al. 2015; Laux et 
al. 2017) and following repeated exposure (Oberdörster et al. 2000).
Nanoceria has current applications and there is great interest in its potential as a therapeutic 
agent. It has industrial applications that capitalize on its abrasiveness and auto-catalytic 
oxidation/reduction, mediated by reversible oxygen binding at its surface, interconverting 
reduced Ce(III) and oxidized Ce (IV). It is used in chemical mechanical polishing/
planarization (e.g. integrated circuit manufacture) and as a catalyst (in diesel fuel additives, 
solid oxide fuel cells, and other electrochemical devices) (Reed et al. 2014). Capitalizing on 
its auto-catalytic redox, antioxidant/anti-inflammatory, and enzyme-mimetic (nanozyme) 
activity, nanoceria has been assessed and shown, mostly in in vitro studies, to have many 
potential therapeutic applications (Walkey et al. 2015). Results of some in vivo studies 
follow as examples of nanoceria’s therapeutic potential. Repeated iv nanoceria reduced the 
progression of cardiac dysfunction in a transgenic murine (MCP-1) model of 
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cardiomyopathy (Niu et al. 2007), reduced monocrotaline-induced increased ventricular 
hypertrophy and pulmonary arterial pressure (Kolli et al. 2014), and improved microvascular 
reactivity in spontaneously hypertensive rats (Minarchick et al. 2015). Nanoceria 
pretreatment (ip) protected against hypobaric hypoxic-induced inflammatory lung response 
and lung injury in Sprague Dawley rats (Arya et al. 2013). It reduced the number of tumor 
nodules in the peritoneum, bowel, and liver of nude mice after iv injection of A2780 (human 
ovarian carcinoma) cells (Hijaz et al. 2016), advancing in vitro observations of anti-cancer 
activity (Gao et al. 2014). Radiation protection was shown by ip nanoceria before gamma 
radiation to nude mice (Colon et al. 2010) and ip nanoceria injection before and after lethal 
X-ray radiation that increased survival of SHK white outbred mice (Popov et al. 2016). 
Repeated ip nanoceria injections to Wistar rats reduced weight gain and reduced plasma 
insulin, leptin, glucose, and triglycerides, suggesting anti-obesity potential (Rocca et al. 
2015). Antibacterial activity in vitro (Alpaslan et al. 2017) and attenuation of hepatic 
damage and systemic inflammation from lipopolysaccharide-induced sepsis in Sprague 
Dawley rats suggest antimicrobial potential (Selvaraj et al. 2015). Nanoceria ip injection (60 
mg/kg) abrogated some of the adverse effects of streptozotocin-induced diabetes in Wistar 
rats (Navaei-Nigjeh et al. 2012). Repeated iv nanoceria injections reduced carbon 
tetrachloride hepatotoxicity endpoints in rats, suggesting therapeutic potential in chronic 
liver disease (Oró et al. 2016). The potential for repeated iv injections of nanoceria to reduce 
neurodegenerative disease was demonstrated in a model of multiple sclerosis (experimental 
autoimmune encephalomyelitis) in SJL/J mice (Heckman et al. 2013). Beneficial response 
was dose dependent up to a total of 185 mg/kg nanoceria. Nanoceria reduced post-ischemic 
stroke brain infarct volume in rats but beneficial response was not dose linear (Kim et al. 
2012). Beneficial retinal effects have been demonstrated by intravitreal nanoceria injection 
before and after damaging light exposure (reduced photoreceptor cells degeneration) (Chen 
et al. 2006), and subsequent studies by this group. Topical nanoceria accelerated healing of 
biopsy punch-induced skin wounds in C57BL/6 mice (Chigurupati et al. 2013). Oral 
nanoceria after oral ethanol reduced gastric ulcers in Sprague-Dawley rats (Prasad et al. 
2013).
Nanoceria was reported to be insoluble in water, physiological saline, cell culture medium, 
phagolysosomal simulant fluid, and artificial phagolysosomal fluid at pH 4.5 and 5.5, and 
only 0.02% solubilized in 0.1N HCl after 28 days (He et al. 2010, Cho et al. 2012. Geraets et 
al. 2012;Wohlleben et al. 2013; Keller et al. 2014). It persists in vivo for considerable time, 
although, with the exception of the liver, the structural integrity, size and morphology after 
uptake and prolonged residence in vivo are not well defined, especially for different organs 
that harbor the majority of nanoceria after exposure. Following a single iv administration of 
an ~ 30 Nm ceria (aqueous dispersion) to rats, determination of Ce in 13 organs and 2 fluids 
90 days later accounted for 60% of the dose (Yokel et al. 2012). The major sites of nanoceria 
clearance from blood included the liver and spleen, which contained 21 and 15% of the Ce, 
respectively (Yokel et al. 2012). Histology revealed adverse effects in the liver associated 
with micron-sized intracellular nanoceria agglomerations, including the formation of 
granuloma (first seen 30 days after nanoceria administration) that persisted without 
noticeable progression or regression to 90 days after the single nanoceria dose (Tseng et al. 
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2012; Tseng et al. 2014). The average spleen weight of nanoceria-treated rats was 20% 
greater than control rats.
Exactly how in vivo processing of nanoceria affects its toxicological outcomes has yet to be 
determined. Important questions that need to be addressed are: (1) What are the in vivo 
processing variances of nanoceria in different organs; (2) which organ(s) forms secondary 
phases and to what extent and, (3) can dissolution phenomena, phase transformations and 
2nd generation particles/reprecipitation be distinguished for nanoceria in different organs 
using advanced analytical HRTEM applications? To address these issues we investigated the 
in vivo processing of nanoceria in two organs, spleen and liver, which help address 
important questions about local environmental factors. Nanoceria in liver and spleen was 
investigated to assess the extent of particle transformation, including morphological and 
chemical changes, and to identify new reaction products as a result of bioprocessing. The 
main objectives were to identify differences that exist in organ-specific nanoceria processing 
mechanisms including particle breakdown, dissolution, and transformation, and to establish 
relationships among nanoceria processing, biopersistance, and its in vivo stability. The study 
focused on determining the extent of bioprocessing in the two organs using analytical 
HRTEM/STEM and EELS measurements with elemental mapping of cerium, oxygen, and 
phosphorus in select tissue regions.
Materials and Methods
Nanomaterial
Synthesis and characterization of the 5.2% citrate-stabilized cubic nanoceria sterile aqueous 
dispersion used for iv administration of a single high dose to rats was described (Yokel et al. 
2012; Yokel et al. 2013). The synthesized nanoceria was crystalline. It had Miller indices of 
(100), (010), (200), and lesser amounts of (311), and a measured d-spacing of 0.27 Nm for 
(100), as identified by HRTEM (Figure 1). The average primary particle diameter measured 
by TEM was 31 Nm. Dynamic light scattering revealed an average particle size in water of 
41 Nm, with a bimodal distribution of peaks centered at 41 and 273 Nm with peak 
percentages of 100:0% (number basis) and 36:64% (volume basis). The BET-determined 
surface area was 15 m2/g. The zeta potential in water at pH ~ 7.3 was −56 ± 8 mV. As 
synthesized the ceria particles had a slightly reduced valency (more Ce(III) on their surface 
outer rim and a more enhanced valency (less reduction, more Ce(IV)) in the central (core) 
region). The extent of surface citrate coating was ~18%. The free Ce content was << 1%. 
The as synthesized nanoceria is described in more details in Graham et al. 2014.
Animals—The animals (male Sprague Dawley rats) and their housing, diet, and 
monitoring; nanoceria administration; samples collected at termination; and tissue 
preparation and histological evaluation procedures were described III. Nanoceria-treated rats 
received a 1 h iv-infusion of 85 mg/kg nanoceria. This single high dose nanoceria exposure 
was utilized following the toxicology/experimental pathology approach of first determining 
if a novel substance produces effects (hazard identification) to be followed by lower 
exposures to determine the dose-response determination. The high dose was also used to 
maximize the possibility of quantifying cerium by ICP-MS and detecting nanoceria by 
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microscopy up to 90 days later. Given the biopersistence of nanoceria, tissue levels achieved 
after the single high dose might be reached after repeated smaller doses. Initial studies 
showed the dose to be well tolerated (Yokel et al. 2012). Control rats received vehicle 
infusion. Three nanoceria and three control rats were terminated each of 1, 7, and 30 days 
after completion of the infusion. Six control and 7 nanoceria-treated rats were terminated 90 
days after the infusion. They were anesthetized to lack of response to stimulus with 80 
mg/kg ketamine and 10 mg/kg xylazine ip prior to termination. Tissues were harvested from 
the liver and spleen and were fixed in 10% neutral-buffered formalin and processed for 
histopathology analysis. Animal work was approved by the University of Kentucky 
Institutional Animal Care and Use Committee. The research was conducted in accordance 
with the Guiding Principles in the Use of Animals in Toxicology.
Microscopy for Histological Examination
Samples of liver and spleen were cut into 3 mm3 pieces, dehydrated, and embedded in 
Araldite 502. The blocks collected for histology were sectioned to 1 µm thickness and 
stained with toluidine blue for light microscopy screening. Selected blocks were further 
sectioned, mounted on Formvar/carbon coated copper grids (200 mesh, Ted Pella Inc. 
Redding, CA), and examined with a Phillips CM-10 low resolution electron microscope 
equipped with a LaB6 cathode (Phillips Electronic Instruments Co. Eindhoven, The 
Netherlands) operated at 60 kV. Nanoceria-containing Kupffer cells were detected by their 
enlarged size and sinusoidal location in the liver, while Ce-phosphate nanoneedles in the 
white pulp of the spleen were recognized at low resolution as dense agglomerates around 
lymphatic nodules.
HRTEM/STEM, EELS, and EDS Methods
For HRTEM tissue sample blocks were cut to ~ 50–70 Nm thick sections and collected on 
200 mesh Formvar/carbon coated copper grids without staining. Instruments included a 
JEOL 2100F field emission TEM/STEM operated at 200 kV with an analytic pole piece. 
Images were recorded with a Gatan Ultrascan 4k×4k CCD camera and data analysis and 
processing used Gatan Digital Micrograph software. HRSTEM imaging, EELS, and EDS 
were performed with a GATAN HAADF detector, Digiscan II, and Gatan 2000 Image Filter 
(GIF). An Oxford Aztec EDS system, was used for select elemental mapping. All HRSTEM 
images were acquired using an analytical probe with 0.17 Nm resolution. The EELS 
measurements and EELS trace lines were obtained using a 1 Nm probe, an alpha of 12 mrad 
and beta of 6 mrad. Select elemental intensity maps were obtained from core edge intensity 
obtained after background subtraction using an integration window ranging from 10–30 
electron volts depending on the edge of interest (Ce, O, and P edges). A FEI Talos 
transmission and scanning electron microscope was used for fast EDS mapping with a high 
degree of sensitivity due to the wrap around style EDS detector mounted in the objective 
lens. Maps generally took one to two minutes to acquire with a sensitivity great enough to 
detect elemental concentrations in 4 Nm size particles. EDS provides the means to 
determine the relationship between elemental accumulation and tissue regions, particularly 
in a situation where dynamic processes may be in play such as in bioprocessing. This study 
focused on a high dose to obtain excellent EDS signal strength in different organ tissue, but 
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low dose exposure of nanoparticles can also be traced using HRSTEM applications (Graham 
et al. 2017a).
Results
Rats intravenously infused with a single high dose (85 mg/kg) of ~30 Nm ceria displayed 
particle retention in the liver and spleen up to 90 days post infusion. Hepatic and splenic 
granulomas were dispersed throughout the liver as reported previously (Tseng et al. 2012). 
Agglomerates of densely packed nanoceria were found in engorged Kupffer cells (Figure 
2A). Spleen cellular agglomerates are shown in Figure 2B and were comprised of 
intracellular retention of nanoparticles which were particularly abundant in the white pulp. 
Light microscopic examination also revealed that the spleen showed a much greater extent 
of granuloma formation at 90 days compared to the liver. Cerium concentration differences 
in liver versus spleen for various time endpoints up to 90 days post infusion are detailed 
elsewhere (Yokel et al. 2012). Ninety days post infusion the spleen had a much higher 
concentration of Ce (2800 µg/g) than the liver (300 µg/g). At that time histology of the liver 
revealed intracellular agglomerations up to micron size diameter made up of nests of closely 
packed particles (nanoceria and/or Ce-containing degradation products). The agglomerations 
could be linked to adverse effects in the liver including the formation of granuloma seen in 
light microscopy (Figure 2A). The presence of Kupffer cells provided a “marker” for the 
identification of hepatic granuloma, as described in Tseng et al. 2012 and Tseng et al. 2014. 
Large cytoplasmic nanoceria-containing agglomerates were observed in macrophages 
throughout the red and white pulp splenic parenchyma, more abundantly found in the white 
pulp (Figure 2B). In light microscopy we saw dense particles, but could not determine if the 
primary nanoceria particles displayed any transformation inside the organs.
HRTEM revealed structural evidence that nanoceria in the liver was not inert to 
bioprocessing, but was degrading over 90 days (Figures 3A and B). This was evidenced by 
loss of some of the original structure of the as-dosed cubic nanoparticles that exhibited well 
rounded corners after 90 days (Figure 3B), and formation of 2nd generation Ce-containing 
ultrafine (<3 Nm) crystalline particles in the immediate vicinity of the partially degraded as-
dosed nanoparticles (Figure 3B). The 2nd generation particles were significantly smaller than 
the as-dosed nanoparticles and had a different chemical composition (more reduced Ce(III) 
as determined by EELS) than the as-dosed nanoceria (Figure 3D compared to Figure 3C). In 
the EELS spectrum the M4 peak is strongly influenced by Ce(III) while the M5 peak height 
is a relative measure of the presence of Ce(IV). The high M5/M4 ratio (Figures 3D) can be 
linked to high Ce (III) and to anti-oxidant properties as was previously shown for nanoceria 
bioprocessing in the liver (Graham et al. 2014). The morphological and chemical differences 
between the as-dosed (Figure 1) and 2nd generation particles (Figure 3B shows morphology; 
C and D show composition) indicate a dissolution-reprecipitation process occurred. The 
possibility that nanoceria may also undergo bioprocessing in organs other than the liver 
prompted us to examine events in the spleen which contained the highest Ce concentration, 
and 3rd greatest amount of Ce (after liver and bone marrow) that was sequestered after iv 
infusion (Yokel et al. 2012). Nanoceria translocated and accumulated in the spleen (Figure 
3E). Initial scanning of spleen tissue sections in TEM and STEM modes using a high 
resolution probe (0.2 Nm) revealed localized areas with agglomerated, crystalline nanoceria 
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which match the original morphologies and size range of the as-dosed particles (Figure 1), 
but displayed partially missing corners due to dissolution and bioprocessing (Figures 3E and 
F), which were seen with dark field STEM imaging. The degree of bioprocessing occurred 
to a lesser extent compared to nanoceria sequestered in the liver (Figures 3E and F compared 
to Figure 3B). Localized 2nd generation plumes of ultra-fine (0.5–2.5 Nm) nanoparticles 
formed close by, collecting as ultrafine particles next to the partially dissolving primary 
nanoceria (Figure 3F). Corresponding EELS analyses (small probe size (0.2 Nm) to 
minimize beam/tissue interactions) were used to compare the redox state of the as dosed 
primary nanoceria and in vivo precipitated ultra-fines (Figures 3F, G, and H). The Ce 
oxidation states were determined by the fine structures of M4 and M5 edges in EELS spectra 
as described elsewhere (Turner et al. 2011). They indicated that the formation of ultra-fine 
particles was associated with a much improved free radical scavenging potential, evidenced 
by more surface Ce(III) (greater Ce M5 contribution). These results are in agreement with 
earlier findings for the liver (Graham et al. 2014). Although there were limited amounts of 
Ce-phosphate nanoneedles in the liver (typically in lysosomal regions; not shown here), both 
HRTEM and dark field STEM demonstrated significant quantities of Ce-phosphate particles 
in the spleen (Figures 4A-B). Higher magnification shows Ce-phosphate nanoneedles 
(Figures 4C-F). The nanoneedles were localized predominantly within the lymphoid region 
of the spleen white pulp and agglomerated around granules in subcellular regions (Figures 
4A and B). The ultrafine Ce-phosphate nanoneedles are either part of a larger network that 
spanned across several hundred Nm (Figure 4C), or coated the exterior of semi-spherical 
components which resemble lipid structures (Figures 4B and D). In some cases the 
nanoneedles spanned >20 Nm in length (Figures 4E). At atomic resolution it can be seen 
that the nanoneedles are composed of individual self-aligned crystallites (Figure 4F). The d-
spacings (2.81Å) correspond to CePO4. The diffraction pattern reveals the highly crystalline 
nature ofthese particles (Figure 4F). Biodistribution and structural details of the Ce-
phosphate nanoneedles in the spleen are further demonstrated in a video (Supplementary 
File) that was obtained in STEM mode and with a high resolution probe (0.2 Nm).
A Talos F200 STEM with an ultra-high resolution analytical beam at 200kV energy was 
used to obtain better insight into the elemental components of the nanoneedle structures and 
the surrounding host cellular components in the spleen. A relatively larger area containing a 
network of nanoneedles spanning ~ 1 micron in 3D was used for EDS mapping (Figure 5). 
The HAADF-STEM image (Figure 5A) illustrates the nanoneedle agglomerate. 
Corresponding EDS maps indicate a match for O, P, and Ce for each nanoneedle (Figure 
5A), which corroborates the earlier findings that the nanoneedles represent Ce-phosphate. 
Nanoneedles are very thin, giving a greatly reduced EELS signal. The mass of a single 
partially formed nanoneedle (Figure 5B) provided an EELS signal with a sufficient signal to 
noise ratio to assess the M5/M4 ratio. The M5 peak being even with the M4 peak is indicative 
of the presence of Ce(III) and a more reduced state of Ce (Graham et al. 2017a). Further 
work is required to assess the beam dose sensitivity of the nanoneedles so that methods can 
be developed to further access the oxidation state of the needles in greater detail.
A high resolution elemental EDS map was also constructed for individual nanoneedles 
(Figure 5C). Individual crystallites that had self-aligned to form the nanoneedles can be seen 
in the higher resolution EDS map (Figure 5C) which shows perfect overlap for Ce and P in 
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each individual aligned crystallite, where the nanoneedles formed in the spleen. Oxygen was 
also identified, but is not shown in the EDS maps. Iron, corresponding to a ferritin particle 
(biomineralized iron ~ 5 Nm), occurs in the immediate vicinity of the Ce-phosphate 
nanoneedles (Figure 5C). The importance of ferritin nanoparticle formation in regions next 
to invader nanoparticles was described by Graham et al. 2017a. The elemental spectra shown 
in Figure 5D for two select regions, Spectrum 1 (green) taken directly from a selected 
nanoneedle from box 1 in Figure 5C and Spectrum 2 (red) taken from the ferritin 
nanoparticle from box 2, clearly indicate that the nanoneedles are composed of Ce, P, and O 
and do not represent nanoceria that were iv-infused into the rats; the ferritin is composed of 
only Fe and O and represents biomineralized iron. The coexistence of P and nanoneedles 
constitutes a clear difference between liver and spleen since Ce-phosphate is characteristic 
for the spleen and plays a lesser role in the liver.
Discussion
Nanoceria persistence in both the liver and spleen has been shown previously to contribute 
to the observed toxicity in these organs (Tseng et al. 2012). Here we report that the spleen 
shows even more granuloma formation than the liver 90 days after a single nanoceria 
infusion. The observed granulomas in both liver and spleen are the result of the high iv 
exposures and would not be expected in humans. The high dose was chosen to observe 
differences during microscopic analysis. The white pulp contained numerous foci where 
clusters of cells with nanoceria inclusion were observed (Figure 2). The splenic 
microanatomy can be analyzed through its vasculature. Once the lineal artery enters the 
spleen through the hilus, it branches into progressively smaller caliber arteries before 
entering the interior fibrous trabeculae. At that point, they become known as the central 
arteries surrounded by sheaths of enlarging lymphatic tissue to form splenic follicles known 
as the white pulp. The central arteries exiting from the white pulp branch to form the 
penicillar arteries before entering the red pulp of the spleen. While the splenic white pulp is 
essentially made of lymphatic tissue, the red pulp contains the sinuses and the splenic cords 
(Steiniger et al. 2011). Within the splenic cord cavities mixtures of red and white cells are 
abundantly present in the red pulp. This is especially relevant for experimental treatment 
entities including nanoparticles. Through these structural features of the splenic 
microcirculation, invader nanoparticles may permeate throughout the splenic parenchyma. It 
has been reported that more than 90% of the splenic blood flow bypasses the red pulp in 
favour of the white pulp (Schmidt et al. 1993). It highlights the prevalent role of the spleen 
as a lymphoid organ, and suggests that blood-borne entities, including nanoparticles 
(nanoceria), could preferentially affect the white pulp upon entering the spleen, as observed 
in the current study. In contrast, nanoceria uptake in the liver is mainly conducted by Kupffer 
cells and T cells leading to the formation of granuloma (Tseng et al. 2012), but not as 
pronounced as in the spleen.
Instability of nanoparticles after exposure, cellular uptake, in vivo processing, and 
transformation influence nanotoxicity (Graham et al. 2017a). The mechanisms that induce 
toxicity after exposure are poorly understood and thus hinder the building of predictive 
models. Electron microscopy has been fundamental in gaining knowledge about structural, 
compositional, and electronic information of nanoparticles in tissues and can provide 
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information on nanoparticle uptake, biodistribution, and material characterization. We 
discuss below the importance and application of advanced HRTEM to identify the various 
processes involved during in vivo nanoparticle transformation and biodegradation to address 
the in vivo processing of nanoceria in the liver and spleen as a direct response to the uptake 
of invader 30 Nm ceria nanoparticles.
Biodegradation of iron-containing nanoparticles has been described. Degradation of 
superparamagnetic iron oxide nanoparticles (SPIONs) in rat liver was suggested by 
reduction of the dark T2* MRI signal intensity produced by these particles and a reduction 
of Prussian blue staining over 4 weeks (Lee et al. 2010). Using ICP-OES to quantify total 
iron and ferromagnetic resonance and a superconducting quantum interference device 
magnetometer to measure magnetization (intact SPIONs), Levy et al (2011) found a 
decrease in SPION iron in mouse liver, and to a lesser extent the spleen, and increase in non-
SPION iron in the spleen over 90 days. These results suggest SPION degradation in the liver 
and release of iron-containing degradation products that accumulate in the spleen. TEM 
showed a reduction of electron-dense particle size with less-defined contours after 30 days 
compared to the dosed SPIONs, and a lack of nanoparticles at 90 days. Using a 
magnetophoresis technique to measure magnetization in tissue composed of human 
mesenchymal cells, Mazuel et al (2016) observed a decrease of citrate-coated iron oxide 
nanoparticles over 27 days. Their results suggested dissolution of some particles, which was 
confirmed by TEM.
The present study applied sophisticated electron microscopy methods to the study of 
nanomaterial bioprocessing. This is the first utilization of advanced, analytical electron 
microscopy methods, HRTEM, HAADF-STEM, EELS, and EDS mapping, to characterize 
the effects of bioprocessing on the physicochemical properties of nanomaterials in different 
organs. Specifically, we compare bioprocessing effects of intravenously-administered 
nanoceria in liver and spleen samples after a 90 day exposure. These methods were applied 
to elucidate the organ specific cellular and subcellular fate of nanoceria after its uptake. As 
noted in (Mazuel et al. 2016) “Transmission Electron Microscopy (TEM) is the method of 
choice for in situ nanoscale location of nanoparticles within the model tissue and its 
component cells, and for monitoring their individual fate as a function of tissue-maturation”. 
We demonstrated that the in vivo processing, transformation, and cellular effects of 
nanoceria are different in the spleen compared with the liver. In the liver this is characterized 
by primary nanoceria agglomerates with strong dissolution effects including rounded 
surfaces and ultra-fine nanoceria (<3 Nm) in clouds. The spleen also contains nanoceria 
agglomerates that were sequestered from the blood, but the individual particles show less 
dissolution effects (less rounding of the surfaces). HRTEM revealed remnants in the liver of 
the as-dosed nanoceria, but also significant quantities of clouds made up of much smaller 
cerium-containing particles within close proximity to the as-dosed, albeit bioprocessed 
(rounded), nanoceria agglomerates. This suggests that bioprocessing of the primary 
nanoceria and formation of second generation particles in the liver are linked both spatially 
(close distance) and temporally (clouds formed after dissolution of the primary particles). It 
was shown earlier that nanoceria uptake in the liver followed by in vivo processing presents 
with corresponding effects on oxidative stress increases and subsequent decreases and 
coincides with the release of clouds containing ultra-fine nanoceria which have a greatly 
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improved ROS potential compared with the primary particles (Graham et al. 2014; Hardas et 
al. 2014). Changes in numerous oxidative stress, anti-oxidant, cytokine, autophagy, and 
apoptotic markers occurred in the hippocampus over the 90 days after the ~ 30 Nm 
nanoceria administration; a progression through the three tiers of hierarchical oxidative 
stress model for the first 30 days, then a general return to baseline levels 90 days after 
nanoceria administration, a 4th tier (Hardas et al. 2014). This was based on coinciding 
temporal changes in both liver and brain, but there is no direct evidence that 2nd generation 
nanoceria with high Ce(III) activity were translocated to the brain to affect the reversal in 
oxidative stress (Graham et al. 2014; Hardas et al. 2014).
The spleen, unlike the liver, has a very high concentration of Ce-phosphate nanoneedles, as 
shown in Figure 4. Sisler et al. 2016 reported that La2O3 nanoparticle conversion to La-
phosphate nanoparticles (LaPO4) was associated with chronic pulmonary inflammation and 
mild fibrosis in mice. The formation of 2nd generation Ce-and P-containing nanoneedles in 
large 3D networks in the current study is indicative of a precipitation mechanism involving 
Ce-ion containing supersaturated solution and ion transport. We also observed nearly 
spherical structures in the spleen (Figure 4B) that are surrounded/coated by Ce-phosphate 
nanoneedles which further indicates the nanoneedles formed when Ce ions interacted/
reacted with a P-containing surface or membrane. This also requires a Ce-ion transport 
mechanism as indicated in the bioprocessing model in Figure 6. The source for the abundant 
Ce-phosphate nanoneedles in the spleen would require that a large fraction of the primary 
nanoceria was bioprocessed (dissolved) providing abundant Ce ions. However, in the spleen, 
the primary nanoceria show little evidence for dissolution. Therefore, the Ce-phosphate 
nanoneedles in the spleen (Figures 4 and Figure 5) must have formed from Ce ions 
transported to the spleen rather than via bioprocessing of the primary nanoceria that were 
initially cleared by the spleen after iv infusion. Major bioprocessing of nanoceria in the liver 
via dissolution processes and a lack of accumulation of Ce phosphate in the liver indicates 
that some transport of Ce ions from liver to the spleen occurs, as schematically illustrated in 
Figure 6. The decrease of cerium in the liver from 30 to 90 days after a single iv nanoceria 
infusion paired with the concomitant lack of decrease, or increase, in the spleen (Table 1) is 
consistent with Ce ion transport from liver to spleen. Availability of Ce “ions” for 
complexation with regionally accessible phosphate groups in phosphate-rich or depleted 
regions may govern the amount of Ce-phosphate nanoneedles that can form. Some metal 
complexing without nanoparticle precipitation (ion adsorption) may take place even before 
(yellow zone in Figure 6) the Ce ions arrive at phosphate-rich regions (green zone in Figure 
6). Therefore, local ion transport rates will have some control on the rate of formation of Ce-
nanoneedles. Ion transport rates most likely will be affected by the local environment. This 
may explain why we observe 2nd generation nanoparticles in both liver and spleen, but with 
very different amounts. This, in part, is due to the translocation of Ce from liver to spleen 
(Figure 6). Our findings are consistent with previous data that show a decrease of Ce in the 
liver for two doses of nanoceria (6 mg/kg, Yokel et al. 2014; 85 mg/kg, Yokel et al. 2012) 30 
and 90 days after iv administration that was accompanied by an increase in Ce in the spleen. 
A considerable increase in Ce was seen in the spleen by Yokel et al. 2012 after the greater 
dose (85 mg/kg) which is the same dose used in this study (Table 1).
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Comparing the toxicological response of nanoceria to its ion form, it was demonstrated 
using cerium ion instillation into lungs that ion uptake induced a greater initial toxicity than 
the metal nanoparticles and resulted in a high lung retention of Ce (Molina et al. 2014). The 
high retention of Ce (75–92 % at 28 days) in the lung after Ce ion instillation was 
unexpected. Follow-up HRTEM and EELS revealed that in vivo formation of Ce-phosphates 
had occurred (Graham et al. 2017b). Ce-phosphate precipitation observed in the spleen in 
the current study also requires a source of Ce ions which we suggest is a result of the in vivo 
breakdown and dissolution of nanoparticles in the liver (Figure 6). Environmental conditions 
in organ-specific regions where nanoparticles become initially sequestered play a significant 
role in determining the rate of in vivo processing, nanoparticle transformation, and ion 
release rates and diffusion to other locations/organs that results in second generation phases. 
Phosphate serves central biological functions as part of nucleic acids, phospholipids, and 
adenosine triphosphate; as a metabolite involved in energy transfer; as a component of signal 
transduction cascades; and in the regulation of enzymes and metabolic processes (Gu et al., 
2016). Importantly, phosphate functions as an intracellular buffer and plays a central role in 
cellular metabolic pathways (Crook M.A, 2012). It is a critical biochemical, and subtle 
concentration changes can profoundly alter cellular growth. A high-sensitivity methodology 
that would allow for dynamic analysis of inorganic phosphate in subcellular compartments is 
still lacking, but we can clearly see the effects of phosphate availability in the formation of 
the Ce-phosphate nanoneedles in the spleen. Furthermore, we show that available phosphate 
seems to limit the location where nanoneedles are formed (Figure 4) by inducing metal 
precipitation as Ce-phosphate. Nanoceria may adsorb to the phosphate group of 
phosphocholine, a precursor to phosphatidylcholine, a major component of eukaryotic cell 
membranes (Liu and Liu, 2016), that could contribute to the observed distribution of 
nanoceria around membrane-bound intracellular structures. Nanoceria has phosphatase 
mimetic activity, the ability to release terminal phosphate from nucleotides and related 
compounds (Janoš et al. 2017), which may provide some of the phosphate groups seen in the 
Ce-phosphate nanoneedles. Although nanoceria may act as a phosphatase to release 
phosphate, other regions where nanoceria undergoes greater bioprocessing/solubility such as 
inside the liver (Graham et al. 2014), may favor ion transport over phosphate precipitation. 
The formation of Ce-phosphate precipitates that form from available metal ions in tissue was 
previously demonstrated (Berry et al. 1997, Graham et al. 2017b) and is independent of 
nanoceria’s phosphatase mimetic activity, suggesting there are several pathways to form Ce-
phosphate precipitates. We suggest that Ce-phosphate nanoneedle formation may counteract 
the toxicity caused by free Ce ions derived from dissolving (bioprocessing) nanoparticles. 
EELS analysis demonstrates that the Ce-phosphate nanoneedles are composed of reduced 
Ce(III) (Figure 5B), which may contribute to antioxidant properties in vivo. Based on the 
current findings, we propose that the interplay between nanoceria dissolution, ion transport 
to select regions/organs, and re-precipitation as phosphates may influence the availability of 
various metals, including Ce for cellular uptake. The fact that the spleen after 90 days in this 
study was observed to have more granuloma than the liver may be due to a higher Ce ion 
transport into the spleen, since Ce ion exposure was previously shown to induce a greater 
initial toxicity (Molina et al. 2014).
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Biopersistance of nanoparticles typically refers to the elemental concentrations retained in 
tissues rather than the actual nanoparticles, their concentration, structural and morphological 
integrity, chemical composition, redox characteristics, size, or reactive surface area. 
Elemental concentrations cannot distinguish between solids (nanoparticle concentration) or 
released ions which can be readily transported, absorbed, or precipitated after dissolution of 
the primary particles (Figure 6). This limitation/shortfall highlights the importance of 
analytical HRTEM which can determine the dynamic physiochemical changes of 
nanoparticles in tissue sections as a function of residence time and for different organs. In 
vivo processing can affect the transport phenomena and location of primary and second 
generation nanoparticles and their ion counterparts (Graham et al. 2014). Based on the 
findings in the current study we suggest that a first-principles understanding of nanoparticle 
phase stability in cellular and subcellular environments can help to explain structural and 
physicochemical data that is gathered from HRTEM/EELS and serve as a guideline for 
nanoparticle bioprocesses. The current findings further reveal that nanoscale materials 
considered to be biopersistent may undergo bioprocessing in both liver and spleen but have 
different underlying mechanisms. For nanoceria, this does not result in elimination from the 
mammal, but the formation of new, second generation particles that have different 
morphology and chemical composition than the parent materials, and likely, different 
biological properties.
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Figure 1. 
HRTEM image of a cubic ~ 30 Nm nanoceria particle from the dispersion given by iv 
infusion to rats and corresponding diffraction pattern. The dominant face is (100).
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Figure 2. Hepatic and splenic granulomas
(A) Agglomerates of densely packed nanoceria are shown in engorged Kupffer cells in the 
liver (circled area). (B) Cellular agglomerates comprised of intracellular retention of 
nanoparticles are shown to occur abundantly in the spleen white pulp (circled areas).
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Figure 3. Bioprocessing of nanoceria in liver and spleen
(A) shows TEM and (B) shows HRSTEM of nanoceria in the liver. (B) illustrates high 
degree of nanoceria rounding (circled area 1) and clouds of ultrafine particles (circled area 
2).
(C) and (D) show EELS measurements with peak intensities for M4 and M5 at locations 1 
and 2 in (B), respectively.
(E) and (F) show HRSTEM of nanoceria in the spleen with lesser degree of rounding in 
circled area 1 than seen in the liver (Figure 3B); clouds of ultra-fine particles are shown in 
circled area 2.
(G) and (H) show EELS measurements with peak intensities for M4 and M5 at locations 1 
and 2 in (F), respectively.
Graham et al. Page 20
Toxicol Pathol. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 4. HRTEM/STEM images show retention of nanoceria and precipitation of Ce-phosphate 
nanoneedles in the spleen
(A) TEM shows general location of nanoceria in spleen tissue.
(B) HRSTEM illustrates formation of ultrafine precipitates as free networks in location 1 
and as surface coatings around semi-spherical splenic structures in location 2.
(C) HRTEM shows a network of ultrafine nanoneedles from location 1 in (B).
(D) HRTEM illustrates selective location of nanoneedles and single crystallites on splenic 
structures from location 2 in (B).
(E) HRSTEM shows select regions on splenic structures with larger nanoneedles.
Graham et al. Page 21
Toxicol Pathol. Author manuscript; available in PMC 2019 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
(F) HRTEM shows atomic resolution of nanoneedles with corresponding d-spacing and 
diffraction pattern.
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Figure 5. TALOS - EDS mapping
(A) EDS maps of spleen regions containing nanoneedles: HAADF STEM image shows 
nanoneedle networks with corresponding maps for O, P, and Ce in blue, green and yellow, 
respectively.
(B) HAADF-STEM image including a single nanoneedle in the spleen with corresponding 
EELS spectrum of the nanoneedle.
(C) HAADF STEM image (with TEM insert int left upper corner) showing accumulations of 
nanoneedles around splenic structure; red-lined box in TEM insert marks location where 
HAADF STEM image was derived, that included only a few isolated nanoneedles. 
Corresponding EDS map for the nanoneedles shows Fe (red), Ce (yellow), and P (green). 
Red area corresponds to a 4 Nm ferritin nanoparticle. Overlapping yellow and green areas 
correspond to nanoneedles.
(D) Two select EDS spectra obtained for a nanoneedle at location 1 in (C) and a ferritin 
nanoparticle at location 2 in (C).
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Figure 6. 
Schematic comparison of nanoceria bioprocessing in liver and spleen.
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Table 1
Total cerium in the liver and spleen 30 and 90 days after a single iv nanoceria infusion
Results from the 6 mg/kg dose from Yokel et al, 2014, and from the 85 mg/kg dose from Yokel et al, 2012.
Mass amount of cerium in organ (mcg)
30 days after a single iv 30 nm ceria infusion
6 mg/kg
nanoceria dose
85 mg/kg
nanoceria dose
liver 891 4606
spleen 73 1025
90 days after a single iv 30 nm ceria infusion
liver 664 4433
spleen 73 3282
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